While adoptive transfer of the anti-CD133 CAR-T cells alone reduced tumor burden and improved survival in SCLC mouse models, combined anti-PD-1 therapy, CD73 inhibition, and CD133 CAR-T cells resulted in complete remission for 25% of the mice [263]. This evidence concerns the gene PROM1 and neoplasm.